IASTM Contraindications and Precautions: A Clinician’s Guide

Instrument-assisted soft tissue mobilization (IASTM) is used by rehabilitation professionals to address soft tissue impairments and support musculoskeletal rehabilitation. However, appropriate patient selection is essential. Certain conditions may make IASTM inappropriate, while others require additional assessment or modification of the treatment approach.

Understanding IASTM contraindications and precautions helps clinicians identify potential risks and make informed treatment decisions. This guide covers common contraindications, patient-specific precautions, post-treatment bruising, and practical screening steps to help clinicians determine when to proceed, modify, or defer treatment.

IASTM Contraindications vs. Precautions: What's the Difference?

A contraindication is a condition or circumstance in which IASTM should not be performed in the affected context because of potential risk to the patient.

A precaution is a factor that requires additional assessment, closer monitoring, or modification of the treatment approach before proceeding.

These classifications are not always straightforward. A patient's diagnosis, the proposed treatment location, stage of healing, and other individual factors can influence whether treatment is appropriate.

A 2025 modified Delphi study involving 24 international IASTM experts established consensus-based classifications for 39 medical conditions and treatment considerations. These findings provide a foundation for the clinical considerations discussed in this guide, alongside other published guidance and practical screening recommendations.

The researchers categorized conditions as precautions, contraindications, or potentially both, and graded the strength of expert agreement for each classification. The terms strong, moderate, and weak describe the level of expert agreement, not necessarily the severity of clinical risk. These classifications are useful for screening but reflect expert consensus rather than definitive evidence of safety for every patient.

When Is IASTM Contraindicated?

IASTM should be avoided when a patient's condition creates an unacceptable risk associated with the proposed treatment. Common contraindications and treatment-site restrictions include the following:

1. Acute Skin Conditions and Open Wounds

Skin integrity should be assessed before applying an instrument to the treatment area. Strong contraindications identified in the consensus guidance include:

• Open skin wounds
• Skin scrapes and blisters
  
• Acute inflammatory skin conditions
• Insect bites of unexplained origin
  

IASTM should not be performed directly over these areas, as instrument contact may aggravate affected tissue or introduce additional risks.

The study also classified severe skin hypersensitivity and skin rashes as moderate contraindications, while mild to moderate skin hypersensitivity was considered a precaution. These distinctions highlight the importance of assessing the severity and nature of a skin condition before treatment.

2. Acute Infection and Systemic Illness

Acute systemic bacterial or viral infection, fever, and contagious conditions were classified as strong contraindications.

When these conditions are present, clinicians should defer IASTM until the acute condition has resolved and the patient is appropriate for treatment. Considerations include the patient's overall health and the potential for transmitting infection.

Flu or flu-like symptoms were separately classified as a moderate precaution, emphasizing the need to assess the patient's symptoms and clinical status rather than treating every respiratory symptom identically.

3. Vascular, Bleeding, and Bone-Related Risks

Conditions affecting vascular health, bleeding, and bone stability require particular attention. Strong contraindications include:

• Thrombophlebitis
• Osteomyelitis
• Unhealed or unstable bone fractures
  

Thrombophlebitis involves inflammation of a vein, often associated with a blood clot, and mechanical pressure over the affected area may present a serious risk. Osteomyelitis is a bone infection that requires appropriate medical management.

Bleeding disorders, such as hemophilia, were classified as moderate contraindications. Clinicians should consider the patient's bleeding history and relevant medical guidance before proceeding with IASTM.

Unhealed bone stress fractures were classified as potentially either a precaution or a contraindication, depending on the clinical context. Treatment decisions should account for the injury, healing status, and proposed treatment site.

4. Other Contraindications and Treatment-Site Restrictions

Other contraindications and treatment-site considerations include:

• Allergies to metals, emollients, or latex: Classified as strong contraindications when the relevant material is involved in treatment. Clinicians should verify instrument and product materials and select appropriate alternatives when necessary.
• Myositis ossificans: A condition involving bone formation within soft tissue, classified as a moderate contraindication.
• Polymyositis: Classified as a weak contraindication, reflecting a lower level of expert agreement.
• Pacemakers and insulin pumps: Treatment around these devices was classified as a moderate contraindication. Clinicians should consider device location and the proposed treatment area.
• Direct pressure over vulnerable structures: Pressure over the face, eyes, bony prominences, arteries, veins, or nerves was classified as a weak contraindication.

IASTM Precautions: When Should Clinicians Modify Treatment?

A precaution does not automatically rule out IASTM. Instead, it signals the need to evaluate potential risks and determine whether the treatment parameters, location, or timing should change.

Common precautions and situations requiring individualized clinical judgment include the following:

1. Medications and Bleeding Risk

Blood-thinning medications were classified as moderate precautions in the consensus study. These medications may increase the risk of bruising or bleeding following mechanical pressure.

Clinicians should review the patient's medication history and consider relevant bleeding risks before treatment.

The study also identified certain other medications, including hormone replacement therapy and fluoroquinolone antibiotics, as moderate precautions. These classifications call for an individualized review of medication history and relevant clinical risks rather than automatically ruling out IASTM.

When the implications of a medication or underlying condition are unclear, clinicians should seek appropriate medical guidance before proceeding.

2. Sensory Changes and Pain Sensitivity

Altered skin sensation, including numbness and tingling, was classified as a weak precaution. Medications that alter sensation and severe pain were also identified as precautions requiring clinical consideration.

These factors may affect treatment tolerance and the patient's ability to provide reliable feedback. Clinicians should assess sensation and pain response before treatment and determine whether the patient can communicate discomfort or changes in symptoms during the intervention.

If reliable feedback is not possible and the associated risks cannot be adequately managed, clinicians should modify or defer treatment or consider an alternative intervention.

3. Chronic Conditions and Complex Clinical Histories

Some conditions were classified as potentially either precautions or contraindications, depending on the clinical context.

The 2025 study identified the following:

• Peripheral vascular disease or insufficiency
• Varicose veins
• Cancer or malignancy
• Lupus
• Healing surgical scars
• High-risk pregnancy

Dupuytren's contracture and an inability to communicate were also identified as conditions that may fall into either category.

For these situations, clinicians should consider the patient's overall condition, proposed treatment site, stage of healing when relevant, and risks associated with the intended application.

For example, a healing surgical scar may require a different decision depending on its healing stage and whether treatment is proposed directly over the scar or elsewhere on the body.

IASTM Contraindications and Precautions: What Does the Research Say?

Research on IASTM safety provides useful guidance, but important evidence gaps remain. Much of the available guidance is based on expert consensus and clinical recommendations rather than studies directly evaluating the safety of IASTM across different patient populations.

The 2025 international expert-consensus study discussed throughout this guide provides a framework for classifying contraindications and precautions. However, consensus reflects expert judgment and does not establish that IASTM is safe or unsafe in every clinical scenario.

A 2019 clinical commentary on IASTM practice guidelines also addressed patient screening, precautions, and adverse treatment responses while highlighting limitations in the available evidence. More recently, a 2025 exploratory survey examined healthcare professionals' agreement with expert recommendations, offering insight into how clinicians interpret IASTM safety guidance.

Together, these publications reinforce the importance of individualized assessment. Existing recommendations can help clinicians identify potential risks, but they should be applied alongside the patient's medical history, clinical presentation, and response to treatment rather than treated as definitive rules for every situation.

IASTM Bruising: What Clinicians Should Know

Visible skin changes following IASTM require careful interpretation. Clinicians should understand the difference between petechiae and ecchymosis and recognize that neither is a required treatment outcome.

Petechiae are small, pinpoint spots caused by bleeding from tiny blood vessels near the skin's surface. Ecchymosis refers to a larger area of discoloration commonly described as bruising.

A 2019 clinical commentary on IASTM practice guidelines advised against deliberately producing petechiae or ecchymosis because these changes may indicate tissue trauma. It recommended reassessing the application when petechiae develop and refraining from further treatment when ecchymosis is present at the treatment site.

Visible bruising should not be used as a measure of treatment effectiveness. This is one of several common misconceptions about IASTM that clinicians should consider when evaluating treatment responses.

How Should Clinicians Respond to IASTM Bruising?

If bruising or unexpected skin discoloration develops during or after treatment, clinicians should:

• Reassess the treatment application and the patient's response.
• Avoid further IASTM over the affected area until it has been assessed and has recovered appropriately.
• Consider relevant risk factors, including anticoagulant use and bleeding disorders.
• Seek appropriate medical assessment if discoloration persists or worsens, pain is unusual or severe, or other concerning symptoms develop.
• Document the response and review the treatment approach before any subsequent session.

Skin changes should be interpreted in the context of the patient's medical history, the treatment performed, and the nature of the observed response.

Practical IASTM Safety Checklist

A consistent screening and monitoring process helps clinicians identify potential risks and make informed treatment decisions.

• Review: Check medical history, medications, allergies, recent injuries, and relevant procedures.
• Inspect: Examine the intended treatment area for skin changes, wounds, swelling, or discoloration.
• Assess: Consider sensation, pain response, vascular concerns, and the suitability of the treatment site.
• Decide: Proceed, modify, defer, or avoid treatment based on the assessment.
• Monitor and document: Record the patient's response and any adverse effects, and reassess before subsequent sessions.

This checklist supports clinical judgment but does not replace a comprehensive patient assessment.

Applying IASTM Safely in Clinical Practice

Safe IASTM application requires appropriate patient screening, an understanding of contraindications and precautions, and ongoing monitoring of treatment responses. While current expert-consensus recommendations provide a useful framework, treatment decisions should always reflect the patient's individual clinical presentation.

Appropriate training can also help clinicians develop their instrument-handling skills, understand treatment parameters, and recognize responses that warrant reassessment. To continue developing these skills, explore HawkGrips IASTM courses for professional education and training.